U.S., April 9 -- ClinicalTrials.gov registry received information related to the study (NCT07516548) titled 'Pharmacokinetic Study of Long-acting Antiretrovirals and Contraceptives in HIV' on March 04.
Brief Summary: This study is being done to understand how long-acting injectable cabotegravir (CAB-LA) used for HIV pre-exposure prophylaxis (PrEP) and hormonal contraceptive methods affect each other when used at the same time. Women who are already using CAB-LA or not using PrEP will choose to join one of several groups based on whether they use injectable contraceptive (IM DMPA), an etonogestrel implant, or no hormonal contraceptive. Participants will have study visits every 4 to 12 weeks for up to 12 or 24 weeks after starting a contrace...